Granules India Shares Escalates By 8% Post Drug Approval

By Archana L
Subscribe to GoodReturns
For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

    The shares of Granules India - the Hyderabad based pharmaceutical manufacturing company, surged by over 8% in the backdrop of the company receiving approval from U.S. Food and Drug Administration (FDA) to its Methylergonovine 0.2mg Tablets.

    Granules India Shares Escalates By 8% Post Drug Approval

    Methylergonovine is a semi-synthetic ergot alkaloid used for the prevention and control of postpartum hemorrhage.

    The product Methylergonovine 0.2 mg tablet is a low competitive drug with sizable volumes and the launch of the product in India will in-turn benefit the company.

    Food and Drug Administration-popularly known as FDA, is a federal agency of the United States Department of Health and Human Services.

    The role of FDA is to protect and promote the public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines and so on.

    This approval has come from the company's US facility, which will start building a pipeline from its facility located in Virginia, US. The current facility in the United States is an acquired facility and the company has chalked out plans to start adding value-added products from this facility.

    The company plans to develop around 5-6 Abbreviated New Drug Application (ANDA) per year. Once the company starts launching products from this site, there will be operating leverage which will lead to the expansion of margins.

    The stocks of the company were trading at Rs 105.25 per piece, up by 8.79% at 12:58 pm (IST) in BSE.

    Read more about: fda shares stocks
    Company Search
    Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'

    Find IFSC

    Get Latest News alerts from Goodreturns

    We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more